Universal. Short. Yours
The leading experts of Russia, the United States, France, Great Britain and Spain discussed modern approaches to the therapy of liver diseases within the framework of the 10 th International Conference «White Nights of Hepatology» held in St. Petersburg on May 31 - June 1, 2018. The reports on the market authorization in Russia of the first eight-week pan-genotypic fixed-dose combination Maviret (glecaprevir / pibrentasvir) for the treatment of chronic hepatitis C (CHC) and new revolutionary perspectives for patients had great resonance.